{"url_path":"/sec/imvt/10-k/2026/item-3","section_key":"item-3","section_title":"Item 3 Legal Proceedings","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1764013/0001764013-26-000064-index.html","accession_number":"0001764013-26-000064","cik":"0001764013","ticker":"IMVT","issuer_name":"Immunovant, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1764013/0001764013-26-000064-index.html","primary_entity_key":"0001764013","primary_entity_name":"Immunovant, Inc."},"word_count":104,"has_tables":true,"body_markdown":"Item 3.    Legal Proceedings\n\nFrom time to time, we have been and may become involved in legal or regulatory proceedings arising in the ordinary course of our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, operating results or financial condition. However, depending on the nature and timing of a given dispute, an unfavorable resolution could materially affect our current or future results of operations or cash flows.\n\nFor a description of our legal proceedings, see Part II, Item 8. Financial Statements and Supplementary Data, Note 10 – Commitments and Contingencies for more information."}